FDA launches Rare Disease Framework Initiative to reshape drug development for small patient populations

The FDA announced a new Rare Disease Framework Initiative aimed at overhauling how drugs and biologics for rare conditions are developed.

The initiative will produce a tailored framework that reflects each disease’s specifics, patient needs, product type, and the type of evidence feasible in limited patient groups. The agency will seek input from patients, advocates, industry and others at a meeting on Oct 28 at its White Oak campus, organized with the Reagan-Udall Foundation.

HHS Secretary Robert F. Kennedy Jr emphasized that the current one‑size‑fits‑all approach does not serve rare‑disease patients, and the FDA intends to cut unnecessary hurdles, adopt advanced science and speed promising therapies while keeping rigorous standards.